About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Speaker: Dr. Ling Peng, Research director in the Interdisciplinary Center on Nanoscience in Marseille (CINaM) at the French National Scientific Research Center (CNRS) France.
Abstract: The application of nanotechnology is widely expected to bring breakthrough in medicine for disease treatment and diagnosis. Dendrimers are ideal precision materials for elaborating nanomedicine by virtue of their well-defined structure, multivalent cooperativity and nanosize per se. We have pioneered modular and adaptive self-assembling dendrimer nanosystems1 for the delivery of anticancer drugs,2 nucleic acid therapeutics3 and imaging agents4 for cancer detection and treatment. Remarkably, these supramolecular dendrimer nanosystems are able to exploit the in situ tumor-secreted extracellular vesicles for effective delivery and deep penetration in tumor tissue, while overcoming tumor heterogeneity and dynamic evolution.2 Also, we have recently developed self-assembling dendrimers against infectious diseases caused by multidrug-resistant pathogens.5 Our findings offer a fresh perspective for exploiting the advantageous features of supramolecular dendrimers to reach the ultimate goal of nanomedicine.
Host: Dr. Fernanda Raquel da Silva Andrade, Main researcher Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT).
Online attendance: https://gencat.zoom.us/j/86581646343